Kodiak的DAYBREAK 3期試驗——Zenkuda與KSI-501的頂線數據預計於2026年9月公布

The 8-K confirms the DAYBREAK Phase 3 study of Zenkuda and KSI-501 in treatment-naïve wet AMD remains on track for one-year primary endpoint topline data in September 2026. Enrollment is complete and the company continues BLA preparation activities for Zenkuda. A second Phase 3 readout for KSI-101 in MESI is also guided for December 2026.

關鍵事實

申報時間: 2026年8月13日下午08:00
事件: 主要結果 (Topline)
方向: 中性
公司: KODKodiak Sciences
資產: Zenkuda
來源: SEC 8-K
可信度: 有出處
DRSS 2步改善: 62.5% vs 3.3%（p<0.0001）
STC風險降低: 85%（2.4% vs 15.8%，p=0.0001）

來源摘錄

EX-99.1 2 kod-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results PALO ALTO, Calif., August 13, 2026 -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the second quarter ended June 30, 2026. "Kodiak continues to execute broadly across our late-stage clinical portfolio as we approach three Phase 3 readouts between now and the end of this year," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences. "We remain on track for September 2026 DAYBREAK Phase 3 topline results evaluating both Zenkuda and KSI-501 in treatment-naïve wet AMD, followed by December 2026 PEAK Phase 3 Pivotal Analysis 1 topline results evaluating KSI-101 in Macular

SEC 8-K